This article is more than 5 years old. Information may no longer be current.
Reading speed improves in patients with RVO after anti-VEGF injections
Monthly injections of ranibizumab improved reading speed in patients with macular edema secondary to retinal vein occlusion, according to a study.
The analysis was derived from the 789 patients with branch or central retinal vein occlusion who took part in the multicenter, double-masked phase 3 BRAVO and CRUISE trials.
Sham treatments were administered to 132 BRAVO patients and 130 CRUISE patients; intravitreal injections of Lucentis 0.3 mg (ranibizumab, Genentech) were administered to 134 BRAVO patients and 132 CRUISE patients; and intravitreal injections of ranibizumab 0.5 mg were administered to 131 BRAVO patients and 130 CRUISE patients.
At 6 months, patients with BRVO who received ranibizumab 0.5 mg gained a mean 31.3 words per minute (wpm) in reading speed, compared with a gain of 15 wpm gain in sham-treated eyes (P = .007).
Patients with BRVO who received ranibizumab 0.3 mg gained 21.9 wpm; the difference was statistically significant compared with sham-treated eyes (P = .036).
Patients with CRVO who received ranibizumab 0.5 mg gained 20.5 wpm, compared with a gain of 8.1 wpm in sham-treated eyes (P = .01).
Patients with CRVO who received ranibizumab 0.3 mg gained 23.7 wpm; the difference was statistically significant compared with sham-treated eyes (P = .001).